Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)
- Conditions
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Canadian Heart Research Centre
- Target Recruit Count
- 391
- Registration Number
- NCT00131664
- Locations
- 🇨🇦
Canadian Heart Research Centre, Toronto, Ontario, Canada
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 77
- Registration Number
- NCT00130286
- Locations
- 🇺🇸
Cornell HIV Clinical Trials Unit, Weill Medical College of Cornell University, New York, New York, United States
🇺🇸AIDS Community Research Initiative of America (ACRIA), New York, New York, United States
🇺🇸St. Luke's-Roosevelt Hospital Center, New York, New York, United States
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- St. Paul Heart Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00123643
- Locations
- 🇺🇸
St. Paul Heart Clinic, St. Paul, Minnesota, United States
Rosiglitazone Plaque Study
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2005-08-01
- Lead Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Target Recruit Count
- 60
- Registration Number
- NCT00123227
- Locations
- 🇬🇧
St Mary's NHS Trust, London, United Kingdom
🇬🇧Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, United Kingdom
South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-06-19
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT00121966
- Locations
- 🇩🇰
Diabetes Research Center, Odense, Denmark
Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis
- Conditions
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Rosiglitazone Versus Theophylline in Asthmatic Smokers
- Conditions
- Interventions
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- University of Glasgow
- Target Recruit Count
- 79
- Registration Number
- NCT00119496
- Locations
- 🇬🇧
Asthma Research Group, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom
Use of Rosiglitazone in the Treatment of Endometriosis
- Conditions
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2012-10-17
- Target Recruit Count
- 25
- Registration Number
- NCT00115661
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
- Conditions
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110851
- Locations
- 🇺🇸
Endocrine Clinical Research, Winter Park, Florida, United States
🇺🇸Neem Research Group, Columbia, South Carolina, United States
🇺🇸Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
- Conditions
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2009-11-10
- Lead Sponsor
- Gerstein, Hertzel, MD
- Target Recruit Count
- 5000
- Registration Number
- NCT00095654
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.